Sutro Biopharma, Inc.

NASDAQ:STRO

Biotechnology

Healthcare
$8.50 +1.13%

+$0.32 today

Market cap
$141.11M
Beta
1.55
P/E (TTM)
-0.0
EPS (TTM)
-$1,174.12
52W Low $6.70High $43.85

Volume 0.31M

Average 0.28M

STRO Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Sutro Biopharma, Inc.NASDAQ: STRO

Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026

Selling, general & admin declines year over year

Q1 FY2026 selling, general & admin of $7.58M fell 42.9% year over year, behind the -27.9% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 12.4% from the prior quarter. Over 3 fiscal years it compounded at -11.7% a year.

Context

  • Selling, general & admin amounted to 40.0% of revenue in FY2025, down 38.1 pp from a year earlier.
  • Selling, general & admin increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 9 analysts of $32.4M (-21.0%) for the fiscal year ending Dec 2026, a slowdown from the -15.3% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$7.58M-12.4% QoQ
Last fiscal yearDec 2025
$41.02M-15.3% YoY
LTMMar 2026
$35.33M-27.9% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-42.9%-22.0%+20.9 pp
1 year-15.3%-21.0%-5.7 pp
3-year CAGR-11.7%-13.6%-2.0 pp
5-year CAGR+4.8%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
41.02M USD
Year-over-year change
-15.3%
4-year CAGR
-7.5%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How STRO compares with its peers on the latest reported figures

  • Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -27.9% is the 6th highest of 8, against a peer median of -13.9%.
  • Selling, general & admin amounts to 35.5% of revenue for STRO, versus a peer median of 16758.9%.
STRO Competitors
Selling, General & Admin for STRO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PLRXPliant Therapeutics, Inc.LTM Mar 2026$39.91M USD-32.7%+5.7%—
STROSutro Biopharma, Inc.LTM Mar 2026$35.33M USD-27.9%-11.7%35.5%
DTILPrecision BioSciences, Inc.LTM Mar 2026$30.49M USD-13.9%-7.9%67.6%
CNTBConnect Biopharma Holdings LimitedFY2025$20.34M USD+5.8%-0.8%31781.3%
ARTVArtiva Biotherapeutics, Inc.LTM Mar 2026$20.27M USD+8.2%-0.8%—
STTKShattuck Labs, Inc.LTM Mar 2026$17.37M USD-6.9%-4.3%1736.5%
GUTSFractyl Health, Inc. Common StockLTM Mar 2026$17.25M USD—+15.2%—
KLRSKalaris Therapeutics IncLTM Mar 2026$15.32M USD-41.8%+90.0%—
IFRXInflaRx N.V.LTM Mar 2026€14.24M EUR-27.6%+7.0%48538.7%
Peer median (excluding STRO) —-13.9%+2.5%16758.9%

Competitors are the stored peer set for STRO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue61.88M67.77M153.73M62.04M102.48M
Cost of Revenue9.77M8.29M6.82M7.22M7.32M
Gross Profit52.11M59.48M146.92M54.83M95.16M
Gross Margin84.2%87.8%95.6%88.4%92.9%
Research & Development104.4M137.17M180.43M252.04M166.42M
Selling, General & Admin56M59.54M62.58M48.45M41.02M
Operating Expenses150.63M188.43M236.19M293.28M200.11M
Depreciation & Amortization4.84M8.29M6.82M7.22M7.32M
EBITDA(97.56M)(105.07M)(67.92M)(180.45M)(145.65M)
EBITDA Margin-157.7%-155.0%-44.2%-290.9%-142.1%
Operating Income(98.52M)(128.94M)(89.28M)(238.45M)(104.95M)
Operating Margin-159.2%-190.3%-58.1%-384.3%-102.4%
Interest Income577K3.46M14.51M44.43M9.25M
Interest Expense3.14M3.35M23.75M31.07M38.21M
Other Income / Expenses(7.01M)12.24M677K13.36M(86.23M)
Income Before Tax(105.54M)(116.7M)(88.6M)(225.1M)(191.18M)
Pre-Tax Margin-170.6%-172.2%-57.6%-362.8%-186.5%
Income Tax Expense02.5M18.19M2.36M(93K)
Net Income(105.54M)(119.2M)(106.79M)(227.46M)(191.09M)
Net Margin-170.6%-175.9%-69.5%-366.6%-186.5%
EPS (Basic)(22.90)(23.50)(17.80)(29.60)(22.49)
EPS (Diluted)(22.90)(23.50)(17.80)(29.60)(22.49)
Weighted Avg Shares4.61M5.07M6.02M7.68M8.5M
Weighted Avg Shares (Diluted)4.61M5.07M6.02M7.68M8.5M

Sutro Biopharma, Inc.

NASDAQ:STRO

Intrinsic Alpha fair value

Locked

Current Price

$8.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.